News
Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...
U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...
Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...
It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.
The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...
Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...
Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...
Merck starts construction on a $1B biologics facility in Wilmington, Del., expected to create 500+ jobs and support Keytruda production.
Merck (MRK) is reportedly looking to expand its U.S. manufacturing presence with a $1 billion facility in Delaware, becoming ...
Officials with Merck Biopharmaceutical Company broke ground on a new, 470,000 square foot biologics center at the Chestnut ...
Merck estimates the project will create more than 500 full-time roles and about 4,000 construction jobs. CEO of Main Line ...
The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback